| ²é¿´: 914 | »Ø¸´: 2 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßmayanhong_½«ÔùËÍÄú 150 ¸ö½ð±Ò | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
mayanhong_½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖú5ƪӢÎÄÎÄÏ×
|
|
|
1¡¢Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice Laura Evgin 1, Tim Kottke 1, Jason Tonne 1, Jill Thompson 1, Amanda L Huff 1, Jacob van Vloten 1, Madelyn Moore 1, Josefine Michael 1, Christopher Driscoll 1, Jose Pulido 1, Eric Swanson 2, Richard Kennedy 2, Matt Coffey 3, Houra Loghmani 3, Luis Sanchez-Perez 4, Gloria Olivier 5, Kevin Harrington 6, Hardev Pandha 7, Alan Melcher 6, Rosa Maria Diaz 1, Richard G Vile 1 8 Affiliations expand PMID: 35417192 DOI: 10.1126/scitranslmed.abn2231 2¡¢Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. Zarezadeh Mehrabadi A, Roozbahani F, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R, Esmaeili Gouvarchin Ghaleh H.World J Surg Oncol. 2022 Jan 13;20(1):16. doi: 10.1186/s12957-021-02486-x.PMID: 35027068 Free PMC article. Review. 3¡¢Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects. Chowdhury S, Bappy MH, Clocchiatti-Tuozzo S, Cheeti S, Chowdhury S, Patel V.Cureus. 2021 Dec 22;13(12):e20604. doi: 10.7759/cureus.20604. eCollection 2021 Dec.PMID: 35103180 Free PMC article. Review. 4¡¢Polymeric Systems for Cancer Immunotherapy: A Review. Le TMD, Yoon AR, Thambi T, Yun CO.Front Immunol. 2022 Feb 22;13:826876. doi: 10.3389/fimmu.2022.826876. eCollection 2022.PMID: 35273607 Free PMC article. Review. 5¡¢Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. Aalipour A, Le Boeuf F, Tang M, Murty S, Simonetta F, Lozano AX, Shaffer TM, Bell JC, Gambhir SS.Mol Ther Oncolytics. 2020 Apr 7;17:232-240. doi: 10.1016/j.omto.2020.03.018. eCollection 2020 Jun 26.PMID: 32346612 Free PMC article. |
» ²ÂÄãϲ»¶
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ78È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ16È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´
mayanhong_
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1321.7
- Ìû×Ó: 63
- ÔÚÏß: 83.4Сʱ
- ³æºÅ: 745586
- ×¢²á: 2009-04-10
- ÐÔ±ð: MM
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
3Â¥2022-04-24 09:02:18














»Ø¸´´ËÂ¥